Anthem Biosciences

Executive Summary

Anthem Biosciences is a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Bangalore, India. Founded in 2006, the company provides end-to-end services for small molecules, peptides, lipids, oligonucleotides, and biologics. Leveraging advanced platforms such as biocatalysis, flow chemistry, micellar chemistry, and microbial/mammalian biologics, Anthem serves clients from discovery through commercial supply. With over 1,000 employees and a strong focus on therapeutic spectrum coverage, the company has established itself as a trusted partner for global pharmaceutical and biotech firms seeking cost-effective, scalable development and manufacturing solutions. The global CRDMO market is expanding rapidly, driven by increasing R&D outsourcing and demand for complex molecules. Anthem is well-positioned to benefit from this trend, particularly in biologics and oligonucleotides. However, the company faces competition from larger players and must manage regulatory compliance across geographies. Its recent investments in capacity expansion and technology differentiation are likely to sustain growth. We assign a conviction score of 75, reflecting solid fundamentals and market tailwinds, tempered by execution risks in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Completion of new biologics manufacturing facility85% success
• Q4 2026FDA approval of a client drug manufactured by Anthem60% success
• H1 2027Announcement of strategic partnership with a top-20 pharma company50% success